Clinical and laboratory predictors of effectiveness of background therapy in rheumatoid arthritis


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The evaluation of clinical and laboratory predictors of the effectiveness of combination therapy with methotrexate and infliximab in rheumatoid arthritis (RA) was performed. A 30-week study included 18 patients with RA. It has been established that background anti-inflammatory therapy in combination with genetically engineered biologic drugs leads to a significant improvement in clinical and laboratory indicators (a marked decrease in the of acute phase inflammatory marker levels, normalization of the hemogram) and the quality of life of patients with high RA activity.

Full Text

Restricted Access

About the authors

S. S Dotsenko

FSBEI HE "Volgograd State Medical University" of RMH

Email: svetlanahime@yandex.ru
Postgraduate Student at the Department of Hospital Therapy, MFT with the course of Clinical Rheumatology DIF

L. N Shilova

FSBEI HE "Volgograd State Medical University" of RMH

References

  1. Dinarello C.A., Moldawer L.L. Proinflammatory and antiinflammatory cytokines in rheumatoid arthritis. A primar for clinicians. 3rd edition. Amgen Inc. 2002. P. 351.
  2. Olsen N.J., Stein C.M. New drugs for rheumatoid arthritis. New Engl. J. Med. 2004;350:2167-79.
  3. El-Gabalawy H.S., Lipsky P.E. Why do we not have a cure for rheumatoid arthritis? Arthritis Res. 2004;4(Suppl. 2):297-301.
  4. Насонов Е.Л. Перспективы фармакотерапии воспалительных ревматических заболеваний: моноклональные антитела к фактору некроза опухоли. РМЖ. 2001;9:7-9.
  5. Lorenz H.M., Kalden J.R. Perspectives for TNFa targeting therapies. Arthritis Res. 2002; 4:S17-24.
  6. Kalden J.R. Emerging role of antitumor necrosis factor therapy in rheumatic disease. Arthritis Res. 2002;4:34-40.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies